GeneOne Life Science, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 8,723.29 million compared to KRW 8,750.19 million a year ago. Net loss was KRW 11,557.5 million compared to KRW 7,904.28 million a year ago. Basic loss per share from continuing operations was KRW 148 compared to KRW 102 a year ago. Diluted loss per share from continuing operations was KRW 148 compared to KRW 102 a year ago. Basic loss per share was KRW 148 compared to KRW 102 a year ago.
For the nine months, sales was KRW 18,248.35 million compared to KRW 26,785.69 million a year ago. Net loss was KRW 37,966.87 million compared to KRW 23,499.64 million a year ago. Basic loss per share from continuing operations was KRW 489 compared to KRW 303 a year ago. Diluted loss per share from continuing operations was KRW 489 compared to KRW 303 a year ago. Basic loss per share was KRW 489 compared to KRW 303 a year ago.